Novocure says CMS rescinds revocation of billing privileges

Novocure (NVCR) disclosed that on February 24, it received a letter from Centers for Medicare and Medicaid Services rescinding the revocation of billing privileges and stating the company’s Medicare billing privileges are reinstated retroactively to December 17, 2025. During the period of ineligibility, Novocure continued to provide services to existing patients and accept new patients. The company :believes there will ultimately be no impact to its ability to recognize revenue for these services,” it said in a regulatory filing. Shares of Novocure are up 11%, or $1.28, to $13.02 in premarket trading.